NovaBay Pharmaceuticals, Inc. (NBY) Analysts See $-0.05 EPS; Omnicell, Inc. (OMCL) Covered By 7 Bulls

February 15, 2018 - By reb123z

Among 10 analysts covering Omnicell (NASDAQ:OMCL), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Omnicell had 27 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Thursday, October 19. Cantor Fitzgerald maintained the shares of OMCL in report on Tuesday, December 5 with “Buy” rating. The stock of Omnicell, Inc. (NASDAQ:OMCL) has “Outperform” rating given on Friday, July 31 by Oppenheimer. The firm earned “Buy” rating on Thursday, September 3 by FBR Capital. Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) on Tuesday, December 5 with “Buy” rating. As per Thursday, January 7, the company rating was initiated by Benchmark. PiperJaffray maintained Omnicell, Inc. (NASDAQ:OMCL) on Friday, February 2 with “Neutral” rating. Oppenheimer maintained Omnicell, Inc. (NASDAQ:OMCL) rating on Friday, July 28. Oppenheimer has “Buy” rating and $5300 target. On Thursday, February 1 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Piper Jaffray maintained Omnicell, Inc. (NASDAQ:OMCL) rating on Friday, July 28. Piper Jaffray has “Hold” rating and $4000 target. See Omnicell, Inc. (NASDAQ:OMCL) latest ratings:

02/02/2018 Broker: PiperJaffray Old Rating: Neutral New Rating: Neutral Old Target: $38 New Target: $44 Maintain
02/02/2018 Broker: Craig Hallum Rating: Hold Downgrade
01/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $63.0 Maintain
29/01/2018 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
05/12/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $60.0 Maintain
05/12/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
30/10/2017 Broker: Craig Hallum Rating: Buy New Target: $62.0 Maintain
27/10/2017 Broker: Piper Jaffray Rating: Hold New Target: $38.0 Maintain
27/10/2017 Broker: Oppenheimer Rating: Buy New Target: $55.0 Maintain
26/10/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $58.0 Maintain

Analysts expect NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) to report $-0.05 EPS on March, 22.They anticipate $0.08 EPS change or 61.54% from last quarter’s $-0.13 EPS. After having $-0.16 EPS previously, NovaBay Pharmaceuticals, Inc.’s analysts see -68.75% EPS growth. It closed at $3.6 lastly. It is down 7.90% since February 15, 2017 and is uptrending. It has underperformed by 8.80% the S&P500.

The stock increased 1.69% or $0.72 during the last trading session, reaching $43.72. About 26,705 shares traded. Omnicell, Inc. (NASDAQ:OMCL) has risen 33.21% since February 15, 2017 and is uptrending. It has outperformed by 16.51% the S&P500.

Investors sentiment decreased to 1.02 in 2017 Q3. Its down 0.41, from 1.43 in 2017Q2. It fall, as 8 investors sold Omnicell, Inc. shares while 79 reduced holdings. 29 funds opened positions while 60 raised stakes. 37.10 million shares or 0.94% less from 37.45 million shares in 2017Q2 were reported. California Public Employees Retirement Systems owns 86,240 shares. Castleark Management Limited Liability Corp stated it has 185,305 shares or 0.3% of all its holdings. Kansas-based Waddell & Reed has invested 0.03% in Omnicell, Inc. (NASDAQ:OMCL). Polar Llp holds 443,481 shares or 0.25% of its portfolio. Conestoga Cap Advsr Limited Liability Corp, Pennsylvania-based fund reported 1.62 million shares. Janney Cap Mngmt Limited Liability has 9,484 shares for 0.02% of their portfolio. Assetmark reported 44 shares. Public Employees Retirement Association Of Colorado has 0% invested in Omnicell, Inc. (NASDAQ:OMCL) for 9,027 shares. State Teachers Retirement Sys has invested 0.02% in Omnicell, Inc. (NASDAQ:OMCL). Rockefeller Fincl Serv stated it has 0.46% in Omnicell, Inc. (NASDAQ:OMCL). Bessemer Gp Inc has 45,659 shares. Martin Tn reported 60,565 shares. 245,303 are owned by Tributary Cap Mgmt Ltd Liability. 44,742 were reported by Eam. American Grp holds 29,178 shares or 0.01% of its portfolio.

Since August 15, 2017, it had 0 buys, and 4 sales for $883,828 activity. $552,537 worth of stock was sold by LIPPS RANDALL A on Friday, September 1. The insider Kuipers Peter J. sold $179,998. Shares for $51,734 were sold by PETERSMEYER GARY S. Another trade for 16,400 shares valued at $801,291 was made by JOHNSTON DAN S on Friday, August 18. Seim Robin Gene also sold $768,483 worth of Omnicell, Inc. (NASDAQ:OMCL) on Tuesday, August 15.

Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company has market cap of $1.66 billion. The firm operates through two divisions, Automation and Analytics, and Medication Adherence. It has a 82.5 P/E ratio. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Savvy Mobile Medication Workstation, which provides a platform for hospital information systems.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $55.39 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>